SpanishSpanish    SMSSend SMS
Yashica Pharmaceuticals
Yashica Pharmaceuticals
Yashica Pharmaceuticals

Yashica Pharmaceuticals

Yashica

Yashica PharmaceuticalsYashica Pharmaceuticals

Home » Finished Formulation » Atropine Sulfate Injections

Atropine Sulfate Injections

Serving the society, by delivering qualitative range of medical products, we offer Yashipine Injection that is composed of Atropine Sulfate. It is a sterile and is a non pyrogenic solution. Yashipine Injection is offered in 1MG/ML, 1 ML. Atropine sulfate fights against the adverse actions of neurotransmitter acetylcholine. Healthcare professionals should be consulted before taking the medicine, changing the diet schedule, discontinuing the course in order to maintain the health standards.


Composition:
  • Each mL contains: atropine sulfate USP 1 mg, water for injection USP: q s
Category:
  • Anticholinergic, emergency medications
MOA:
  • It is a competitive antagonist of acetylcholine for a common binding site on the muscarinic receptor.
Pharmacokinetics:
  • It is well absorbed from GI tract. It is distributed throughout the body and readily crosses the blood-brain barrier. It is metabolized in liver and part of the dose is excreted unchanged in urine.
Indications and usage:
  • Pre-operative medication to inhibit secretions and salvation, sinus bradycardia, lessen the degree of atrio-ventricular block, antidote for organophosphorous poisoning or choline esters.
Dosage and administration:
  • Premedication: IV Dose: 0.3 to 0.6 mg immediately before induction of anesthesia and in incremental doses of 0.1 mg for the treatment of bradycardia. IM Dose: 0.3 to 0.6 mg in 30 to 60 minutes before induction.
  • Muscarinic side effects of neostigmine: IV Dose: 0.6 to 1.2 mg
  • Bradycardia: IV Dose: 0.3 to 1.0 mg May be repeated if necessary
  • Organophophorous Poisoning: 2-3 mg parenterally repeat until signs of atropine toxicity
  • Children: Premedication:0.02 mg/Kg
  • Dose for resuscitation of neonates, infants and children: 0.03 mg/Kg by IV
Contraindications:
  • Obstructive disease of GI tract, obstructive uropathy, unstable cardiovascular status in acute haemorrhage, intestinal atony of the elderly or debilitated patient, thyrotoxicosis, tachycardia, hypersensitivity to belladonna alkaloids.
Adverse effects:
  • Dry mouth, decreased sweating, constipation, irritation at injection site, difficulty in swallowing, increased sensitivity to light, confusion, skin rash, orthostatic hypotension, loss of memory, headache, nausea, vomiting, tachyacardia, ventricular fibrillation, palpitation, ataxia.
Special precautions:
  • Reflux oesophagitis, elderly, infants and children, in pregnancy
Drug interactions:
  • Additive anticholinergic effects with quinidine, antidepresents and some antihistamines.
Storage:
  • Store between temperatures 8℃ to 25℃. Protect from light
  • Keep out of reach of children
Presentation:
  • 10 Ampoules of 1 mL in a plastic tray, each tray packed in a printed carton.

Yes! I am Interested

Yashica Pharmaceuticals

Our Product Range :     Active Pharmaceuticals Ingredients |Drug Intermediates | Finished Formulation

Home|About Us|Our Product Range|Media Gallery|Contact Us|Enquiry

Member INDIAMART© Yashica Pharmaceuticals Private Limited. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited

Looking for Product Name ?

x

Send SMS Enquiry

*Please Enter Requirment

*Please Enter valid Mobile Number

*Please Enter Proper Name